Drug Trial Radar · NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4,556
Actual
Start
Sep 27, 2024
Primary completion
Aug 2029
Study completion Oct 2032
Sponsor
- Lead sponsor
- Stemline Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Conditions
- Breast Cancer
Interventions
ElacestrantDrug
Administered as oral tablets
AnastrozoleDrug
Administered as oral tablets
LetrozoleDrug
Administered as oral tablets
ExemestaneDrug
Administered as oral tablets
TamoxifenDrug
Administered as oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Breast Cancer-Free Survival (IBCFS)Time frame: Up to 5 years
Locations
555 sites in 28 countries. Site status is shown where the registry gives one.
Southern Cancer Center, PC
Daphne, Alabama
Ironwood Cancer and Research Centers
Chandler, Arizona
Banner MD Anderson Cancer Center
Gilbert, Arizona
Banner University Medical Center - Phoenix Campus (Banner Good Samaritan Medical Center)
Phoenix, Arizona
Mayo Clinic
Scottsdale, Arizona
Arizona Clinical Research Center, Inc.
Tucson, Arizona
University of Arizona Cancer Center
Tucson, Arizona
Highlands Oncology Group, PA
Springdale, Arkansas
UCSF Cancer Center Berkeley
Berkeley, California
Cedars-Sinai Cancer Beverly Hills
Beverly Hills, California
City of Hope National Medical Center
Duarte, California
UCSF Wash Cancer CNTR
Fremont, California
City of Hope at Irvine Lennar
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
Helios Clinical Research
Long Beach, California
Cancer and Blood Research Center, LLC
Los Alamitos, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California
Pacific Cancer Care - Oncology
Monterey, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
UC Irvine Health, Chao Family Comprehensive Cancer Center
Orange, California
Stanford Women's Cancer Center
Palo Alto, California
Dignity Health dba Health Research Institute
Sacramento, California
Sutter Institute for Medical Research
Sacramento, California
UCSF Zuckerberg SF General
San Francisco, California
University of California, San Francisco (UCSF)
San Francisco, California
Southern California Kaiser Medical Center-San Marcos Medical
San Marcos, California
UCSF Cancer Center San Mateo
San Mateo, California
Sansum Clinic
Solvang, California
Torrance Memorial Physician Network- Cancer Care
Torrance, California
St. Joseph Hospital-Cancer Centers of Colorado
Denver, Colorado
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado
AHMG Hematology and Oncology
Parker, Colorado
Yale New Haven Hospital- Yale Cancer Center
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Sibley Memorial Hospital
Washington D.C., District of Columbia
The George Washington Medical Faculty Associates
Washington D.C., District of Columbia
Florida Cancer Specialists
Fort Myers, Florida
Mayo Clinic
Jacksonville, Florida
Showing 40 of 555 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.